NCT04582539

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

Conditions

• Myelodysplastic Syndromes
• Multiple Myeloma
• Anemia

Interventions

Type	Name	Description
DRUG	INCB000928	INCB000928 will be administered once daily.

Timeline

• Start date: 2021-08-19
• Primary completion: 2024-08-15
• Completion: 2024-08-15
• First posted: 2020-10-09
• Last updated: 2025-10-22
• Results posted: 2025-10-22

Locations

15 sites across 3 countries: United States, France, Italy

Regulatory

• FDA-regulated drug study